Development of a screening tool for migraine prophylaxis;Entwicklung eines Migräneprophylaxe-Screeninginstruments (MPS)

Schmerz

Volumn 21, Issue 5, 2007, Pages 430-438

  Wissmann, A ^a   Feuersenger, A ^a   Gendolla, A ^a   Reuter, U ^b   Straube, A ^c   Evers, S ^d   May, A ^d   Peikert, A ^e   Pfaffenrath, V ^f   Staudenmayer, H ^g   Diener, H C ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e Praxis für Neurologie und Psychiatrie   (Germany)

^f Neurologische Praxis   (Germany)

^g Schmerztherapeutische Praxis Göttingen ^*  (Germany)

Author keywords

General practitioners; Migraine prophylaxis; Questionnaire; Validation study

Indexed keywords

ARTICLE; DISEASE DURATION; HEADACHE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MIGRAINE; PROPHYLAXIS; REST; SCREENING TEST;

HUMANS; MIGRAINE DISORDERS; PROSPECTIVE STUDIES; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 35748966412     PISSN: 0932433X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00482-007-0529-4     Document Type: Article

References (15)

1. Göbel H, Petersen-Braun M, Soyka D (1994) The epidemiology of headache in Germany: a nationwide survey of a representative sample on the basis of the headache classification of the International Headache Society. Cephalalgia 14: 97-106
2. Mortimer MJ, Kay J, Jaron A (1992) Epidemiology of headache and childhood migraine in an urban general practice using Ad Hoc, Vahlquist and IHS criteria. Dev Med Child Neurol 34: 1095-1101
3. Bussone G, Diener H, Pfeil J, Schwalen S (2005) Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int J Clin Pract 59: 961-968
4. Berg J, Stovner LJ (2005) Cost of migraine and other headaches in Europe. Eur J Neurol 12 [suppl 1]: 59-62
5. Diener H-C, Limmroth V, Fritsche G et al. (2005) Therapie der Migräneattacke und Migräneprophylaxe. Leitlinie der Deutschen Gesellschaft für Neurologie und der Deutschen Migräne- und Kopfschmerzgesellschaft. In: Diener H, für die Kommission Leitlinien der DGN (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie, 3. Aufl. Thieme, Stuttgart
6. Goebel H, Heinze A (2002) Die medikamentöse Prophylaxe der Migräne. Schmerz 16: 223-240
7. Silberstein SD, Rosenberg J (2000) Multispecialty consensus on diagnosis and treatment of headache. Neurology 54: 1553
8. Silberstein SD, for the US Headache Consortium (2000) Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommitee of the American Academy of Neurology. Neurology 55: 754-763
9. Meskunas CA, Tepper SJ, Rapoport AM et al. (2006) Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache 46: 766-772
10. Limmroth V, Hubrecht L, Diener HC (2004) Schneller, höher, weiter. Aktuelles zur akuten und prophylaktischen Behandlung der Migräne. Schmerz 18: 398-403
11. Diener HC, Brune K, Gerber WD et al. (2000) Therapie der Migräneattacke und Migräneprophylaxe. Empfehlungen der Deutschen Migräne- und Kopfschmerzgesellschaft (DMKG). Schmerz 14: 269-283
12. Lipton RB, Dodick D, Sadovsky R et al. (2003) A self-administered screener for migraine in primary care: The ID Migraine validation study. Neurology 61: 375-382
13. Olesen J, Bousser M-G, Diener H-C et al., for the International Headache Society (2004) The International Classification Of Headache Disorders, 2nd edn. Cephalalgia 24 [suppl 1]: 1-160
14. Mathers CD, Stein C, Fat DM et al. (2002) Global Burden of Disease 2000: version 2, methods and results. World Health Organization 2002
15. Wober C, Woberbingol C, Koch G, Wessely P (1991) Long-term results of migraine prophylaxis with flunarizine and beta-blockers. Cephalalgia 11: 251-256